Page 50 - Direct To ConsumerFINAL3.25

In Summary
Early detection of HBV and HCV infections allows for timely and effective treatment, significantly improving patient outcomes, and reducing the risk of liver-related complications. Employers who facilitate screening and early diagnosis can potentially improve the health and well-being of their employees while also minimizing the impact of these infections in the workplace.
Footnotes
1. Centers for Disease Control and Prevention (CDC). (2021). Viral Hepatitis Surveillance - United States, 2019. Retrieved from https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm ↩
2. Wasley, A., Kruszon-Moran, D., Kuhnert, W., & Simard, E. P. (2010). The prevalence of hepatitis B virus infection in the United States in the era of vaccination. Journal of Infectious Diseases, 202(2), 192-201. ↩
3. Beltrami, E. M., Williams, I. T., Shapiro, C. N., & Chamberland, M. E. (2000). Risk and management of blood-borne infections in health care workers. Clinical Microbiology Reviews, 13(3), 385-407. ↩
4. Younossi, Z. M., Henry, L., & Bush, H. (2014). Clinical and economic burden of chronic liver diseases in the USA. Journal of Viral Hepatitis, 21(11), 750 ↩
5. Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K. M., Hwang, J. P., Jonas, M. M., ... & Vargas, H. E. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67(4), 1560-1599. ↩ ↩2
6. Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., ... & Dinh, P. (2013). Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. The Lancet, 381(9865), 468-475. ↩
7. Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017). Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Annals of internal medicine, 166(9), 637-648. ↩
8. van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., ... & Manns, M. P. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama, 308(24), 2584-2593. ↩
50